Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy
- Authors
- Park, Seung-Yoon; Kim, In-San
- Issue Date
- 2019
- Publisher
- ELSEVIER IRELAND LTD
- Keywords
- Macrophages; Dendritic cells; Phagocytosis; Antitumer immunity
- Citation
- CANCER LETTERS, v.452, pp.51 - 58
- Indexed
- SCIE
SCOPUS
- Journal Title
- CANCER LETTERS
- Volume
- 452
- Start Page
- 51
- End Page
- 58
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/68973
- DOI
- 10.1016/j.canlet.2019.03.018
- ISSN
- 0304-3835
- Abstract
- Myeloid lineage immune cells, such as macrophages and dendritic cells, play important roles in the induction of antitumor immunity during the initial stage of the cancer-immunity cycle, eliciting antitumor adaptive immunity by phagocytosing cancer cells and processing cancer-specific antigens, and then presenting these antigens to T cells. During this process, cancer cell phagocytosis can be prevented by inhibitory signals, and the signaling cascades that elicit immune responses against cancer antigens can be inhibited by immunosuppressive myeloid cells in the tumor microenvironment. A number of therapeutic strategies for enhancing cancer cell phagocytosis and promoting antitumor immunity by targeting myeloid lineage cells have recently been developed. Here, we discuss recent advances in cancer immunotherapy that involve the targeting of myeloid lineage immune cells to induce effective antitumor immunity.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > KU-KIST Graduate School of Converging Science and Technology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.